Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisTao Li, Jiannan Yao, Huiyun Zhang et al.|Frontiers in Oncology|2021Cited by 12
Early tumor volume change as a novel CT RECIST indicator for predicting pathological response and prognosis in NSCLC patients undergoing immunotherapyFan Xu, Xuming He, Yuanyong Wang et al.|Biomedical Signal Processing and Control|2025Cited by 0